Barton Russell 4

What Happened

• Barton Russell, Chief Operating Officer of Acumen Pharmaceuticals (ABOS), was granted a total of 211,500 equity awards on 2026-01-16: 84,600 restricted stock units (RSUs) and 126,900 derivative awards (stock option-style units). Each line is reported as acquired at $0.00, so the filing shows $0 cash paid.

Key Details

• Transaction date: 2026-01-16; Form 4 filed 2026-01-21 (filed within the SEC’s two-business-day reporting window for this trade date, accounting for the MLK Day holiday).
• Price: $0.00 reported for both awards; total reported cash consideration = $0.
• Shares owned after transaction: not specified in the supplied filing details.
• Footnotes:
  • F1: 84,600 RSUs — each RSU converts to one share at vesting; vests in three equal annual installments beginning one year after the grant, subject to continued service.
  • F2: 126,900 derivative award — shares subject to the option vest in 48 equal monthly installments (fully vested on the fourth anniversary), subject to continued service.
• Transaction code: "A" = grant/award (compensation issuance), not a market buy or sale.

Context

• RSUs are compensatory awards that convert to shares only as they vest; the derivative award is an option-like grant that vests monthly and must be exercised per plan terms before becoming shares. These awards are typical executive compensation and do not reflect an open-market purchase or sale by the insider.